Application of CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer / 国际肿瘤学杂志
Journal of International Oncology
; (12): 617-619, 2019.
Article
in Zh
| WPRIM
| ID: wpr-805852
Responsible library:
WPRO
ABSTRACT
With roles of blocking cell proliferation, cyclin-dependent protein kinase (CDK) 4/6 inhi-bitors are effective and safe complementary therapies for hormone receptor-positive breast cancer. CDK4/6 inhibitors combined with endocrine therapy significantly improve the prognosis of patients with advanced or metastatic breast cancer, especially those with endocrine resistance. Indications for CDK4/6 inhibitors are also expected to broaden into early-stage breast cancer. However, mechanisms of resistance of CDK4/6 inhibitors remain elusive.
Full text:
1
Index:
WPRIM
Language:
Zh
Journal:
Journal of International Oncology
Year:
2019
Type:
Article